Welcome to our dedicated page for BIO KEY INTERNATIONAL SEC filings (Ticker: BKYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIO KEY INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIO KEY INTERNATIONAL's regulatory disclosures and financial reporting.
James D. Sullivan, listed as Chief Legal Officer and SVP Strategy & Compliance of BIO-key International, Inc. (BKYI), reported an open-market purchase of 10,000 shares of common stock on 08/22/2025 at a price of $0.77 per share. After the transaction he beneficially owned 54,851 shares directly; the reported holdings expressly exclude options to purchase 174 shares. The Form 4 indicates this was an individual filing by one reporting person and records the acquisition under transaction code "P." No derivatives or other types of securities were reported in this filing.
BIO-key International, Inc. held its Annual Meeting of Stockholders on August 8, 2025 where shareholders approved two plan amendments. The BIO-key 2023 Stock Incentive Plan was amended to increase the number of shares available for issuance by an additional 700,000 shares while remaining otherwise unchanged. The BIO-key 2021 Employee Stock Purchase Plan was likewise amended to increase available shares by an additional 700,000 shares and was unchanged aside from the share increase. The filing also lists the two amendment exhibits and an embedded Inline XBRL cover page data file.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 359,703 shares of BIO-key International, Inc. common stock, representing 4.99% of the outstanding class. Armistice Capital, a Delaware investment manager, states it exercises shared voting and dispositive power over these shares on behalf of Armistice Capital Master Fund Ltd., the direct holder. Mr. Boyd is identified as the managing member and is reported with the same shared voting and dispositive power.
The filing clarifies the Master Fund retains legal title but disclaims beneficial ownership due to the investment management agreement, and affirms the shares were acquired in the ordinary course of business and not to effect control of the issuer.
BIO-key International, Inc. (BKYI) reported mixed quarterly results with revenue growth but continued losses and a going-concern qualification. For the three months ended June 30, 2025, total revenue was $1,696,907, up from $1,141,286 a year earlier, driven by higher hardware sales and modest license and services growth. Gross profit improved to $1,232,727. The company recorded a net loss of $1,167,396 for the quarter (basic and diluted loss per share $0.20) and a six-month net loss of $1,903,941.
Liquidity changed materially: cash and cash equivalents rose to $2,275,344 from $437,604 at year-end, largely from warrant exercises that generated gross proceeds of approximately $3.8 million and $3,493,505 of net financing cash. Working capital was about $503,000. Management discloses substantial doubt about the company's ability to continue as a going concern without additional financing. Major customer concentration remains (two customers represented 47% of quarterly revenue) and inventory includes a large reserve against finished goods related to delayed projects.
BIO-key International held its Annual Meeting on August 8, 2025 where shareholders elected five directors — Michael W. DePasquale, Wong Kwok Fong (Kelvin), Robert J. Michel, Emmanuel Alia and Cameron E. Williams — each receiving between 995,776 and 1,001,229 votes in favor, with 2,713,111 broker non-votes recorded on those elections.
Shareholders also ratified Bush & Associates CPA LLC as the company’s independent registered public accounting firm (3,500,203 for; 461,100 against; 52,205 abstain), approved the advisory vote on executive compensation (975,360 for; 317,871 against; 7,166 abstain; 2,713,111 broker non-votes), and approved amendments to the 2023 Stock Incentive Plan and the 2021 Employee Stock Purchase Plan with vote totals reported.
BIO-key International filed a Form 8-K reporting that on August 13, 2025 the company issued a press release announcing its second quarter 2025 financial results. The filing states the press release is furnished as Exhibit 99.1 and clarifies that the information is furnished, not "filed," and therefore not subject to Section 18 liabilities or automatically incorporated by reference in other SEC filings.
The report is procedural in nature: it notifies investors that earnings information was released via a press release attached to the 8-K, but it does not include the financial results themselves within the filing.